BioSpace News Archive

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, announced 28-day data from the second dose cohort, at the 100 million cell dose level, in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris.

AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy, for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis.

Sutro Biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα).

Inspira Technologies announced today that it has successfully completed a pump bench study as the company progresses closer towards the manufacturing phase.

TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others.

Esophageal atresia is a condition characterized by an absence of part of the esophagus.

Latest estimates by the American Cancer Society highlight that the United States will witness addition of around 73,750 new patients diagnosed with kidney cancer.

The cryopreservation freezer market may experience extensive growth across the forecast period of 2020-2030 due to the escalating number of biological research clinics and the growing number of government initiatives regarding cell preservation.

EpiEndo Pharmaceuticals, a privately held biopharmaceutical company focused on a novel barrier enhancing approach to the treatment of chronic inflammatory airway diseases such as chronic obstructive pulmonary disease, announces the closing of a €20m Series A financing round led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council Fund joining the round.

Vein stripping is a surgical procedure carried out for the treatment of chronic venous diseases including varicose veins, and the vein stripper is an instrument utilized to remove the vein by tying the vein at one end and pulling it, tearing its branches, and thus, stripping it out of the body